Population of adults, ages 18–49 years in Eswatini, 2011 and 2016^b'*'. by Rejoice Nkambule (470862)

Subjects:

Fig 2 - by Nadine Mayasi Ngongo (11654868)

Subjects:

Proportion of patients initiating ART late overtime. by Nadine Mayasi Ngongo (11654868)

Subjects:

Clinical and immunological status of patients at ARV treatment initiation (N = 7278 people living with HIV with ARV treatment initiated between 2006 and 2017 in Kinshasa). by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of the first-line ART regimen preferentially recommended by the WHO over time. by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of median time between HIV screening and ART initiation, % patients treated within time with ARV treatment initiation year. by Nadine Mayasi Ngongo (11654868)

Subjects:

Proportion of patients who started treatment late according to CD4 and WHO stages and of patients treated within 7 days of diagnosis. by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of the proportion of patients by OMS stage with AVR treatment starting year. by Nadine Mayasi Ngongo (11654868)

Subjects:

Other factors associated with late initiation of ART: Multiple logistic regression models. by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of median CD4 cell count at ART initiation and OMS recommendations. by Nadine Mayasi Ngongo (11654868)

Subjects:

Sociodemographic status of patients at ART initiation (N = 7278 people living with HIV with ARV treatment initiated between 2006 and 2017 in Kinshasa). by Nadine Mayasi Ngongo (11654868)

Subjects:

ART regimen (at ART initiation) (N = 5807), N(%). by Nadine Mayasi Ngongo (11654868)

Subjects:

Construction of Chimeric HIV-1. by Yiying Zhang (198443)

HIV/AIDS infection and drug resistance of heterosexuals under baseline parameters in China. by Xin Jin (108988)

Subjects:

Data_Sheet_1_Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection.PDF by Lerato N. Ndlovu (9315464)

ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses. by LaTonya D. Williams (3140490)

Subjects:

Bayesian logistic regression model posterior intervals of adjusted odds ratios for having tested in the past six months. by Cindy Leung Soo (14509700)

Subjects:

Newly diagnosed and recent HIV infections by province in Rwanda (2018–2020). by Gallican N. Rwibasira (11567195)

Subjects:

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases IgG and IgG1 breadth. by LaTonya D. Williams (3140490)

Subjects:

Prevalence of exposure categories at HIV diagnosis among participants to the HIV-positive cohort at the <i>Clinique médicale L’Actuel</i> in Montréal, Canada, over 1995–2019. by Katia Giguère (146393)

Subjects: